Live feed07:00:00·1191dPRReleasevia Quantisnow89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 WeeksByQuantisnow·Wall Street's wire, on your screen.ETNB· 89bio Inc.Health Care
